Riccesha Hattin, Abbas Hussain, Hazem Aboaid, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Kyaw Zin Thein, Thura Win Htut
{"title":"HSR25-143: 3期随机对照试验的meta分析,以评估贝兰他单抗治疗复发/难治性多发性骨髓瘤患者的全身毒性发生率。","authors":"Riccesha Hattin, Abbas Hussain, Hazem Aboaid, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Kyaw Zin Thein, Thura Win Htut","doi":"10.6004/jnccn.2024.7313","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":"23 3.5","pages":""},"PeriodicalIF":14.8000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.\",\"authors\":\"Riccesha Hattin, Abbas Hussain, Hazem Aboaid, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Kyaw Zin Thein, Thura Win Htut\",\"doi\":\"10.6004/jnccn.2024.7313\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17483,\"journal\":{\"name\":\"Journal of the National Comprehensive Cancer Network\",\"volume\":\"23 3.5\",\"pages\":\"\"},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Comprehensive Cancer Network\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6004/jnccn.2024.7313\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2024.7313","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.
期刊介绍:
JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care.
Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship.
JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.